IMP321
Phase 1Biologic
IMP321 is one of 17 biologic programs targeting Advanced Stage. It is currently in Phase 1.
1
Indications
7
Total Trials
1
Active Trials
16
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
17 competitors in Advanced Stage
#DrugCompanyPhaseTrials
1Adriamycin
PfizerPhase 3
DTIC-Dome
BayerPhase 3
Adcetris
PfizerPhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Vepesid
AAvyxa
Phase 3
Decadron
AAspen Global Incorporated
Phase 3
Nexavar
BayerPhase 2
Tecentriq
RochePhase 2
Stivarga
BayerPhase 2
Imfinzi
AstraZenecaPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Breast Carcinoma2 trials
Advanced Stage1 trial
Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors
Active, not recruiting·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 1·NCT03252938·83 enrolled
Metastatic Melanoma1 trial
Melanoma1 trial
Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides
Terminated·CCliniques universitaires Saint-Luc- Université Catholique de Louvain·Phase 1/2·NCT00365937·19 enrolled
1 more indication
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for IMP321. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- IImmutep S.A.S.